Koninklijke Philips NV Q3 FY2026 earnings call

• Financial Execution: Delivered excellent order intake growth of 8% in Q3 and adjusted EBITA margin of 13%, exceeding expectations. Year-to-date underlying margin expanded by 30 basis points despite inflation.
• Innovation & Product Strategy: Strong traction from AI-enabled innovations including Spectral CT (Verida), helium-free MR (BlueSeal), and Azurion platform. Launched Lumea 9900 Pro in Personal Health. Investing significantly in AI and robotics in the Netherlands and U.S.
• Market Dynamics: North America remains a core growth engine with strong health system consolidation favoring Philips’ integrated platforms. Europe showed robust order intake. China market remains cautious due to centralized procurement pricing pressures, though Personal Health continues to gain share.
• Supply Chain & Quality: Improved service levels year-over-year through dual sourcing and regionalization (e.g., Jakarta distribution center). Continued focus on patient safety and quality systems improvement post-recall.
• Respironics Progress: Reached an agreement in principle with the U.S. Department of Justice, resulting in a EUR 288 million provision. This marks a significant step toward resolving legal consequences, though return to the U.S. CPAP market remains subject to FDA approval.

Diagnosis & Treatment: Comparable sales were broadly flat (mid-single-digit growth in Image-Guided Therapy offset by mid-single-digit decline in Precision Diagnosis). Revenue contribution is not explicitly stated as a percentage, but it is a core segment. Adjusted EBITA margin increased 50 bps to 12.3%. Connected Care: Comparable sales grew 5%. Adjusted EBITA margin increased 190 bps to 13.3% (excluding prior year one-offs, expansion was 340 bps). Personal Health: Comparable sales grew 8%, driven by broad-based growth across regions and platforms like Sonicare and Shaving. Adjusted EBITA margin expanded 60 bps to 17.7%. Other: Sales of EUR 179 million; Adjusted EBITA loss of EUR 12 million.

• Full Year 2026 Comparable Sales Growth: Reiterated at 3% to 4.5%.
• Segment Outlook: Diagnosis & Treatment expected at the upper end of low single-digit growth; Connected Care within 3% to 4.5%; Personal Health upgraded to the lower end of high single-digit growth.
• Adjusted EBITA Margin: Maintained at 13.5% to 14%, including approximately 1% benefit from U.S. tariff refund.
• Free Cash Flow: Maintained at EUR 1.5 billion to EUR 1.7 billion, including approximately EUR 200 million net U.S. tariff refund benefit.
• Net Financial Expenses: Revised downward to approximately EUR 230 million for the full year (previously EUR 240–260 million).
• Productivity Program: On track to achieve EUR 1.5 billion savings target by end of 2028, with EUR 427 million saved year-to-date.

• Legal Proceedings: Respironics-related liabilities continue, with a EUR 288 million provision recorded for the DOJ settlement. Ongoing investigations by U.S. State Attorneys General remain excluded from current guidance.
• China Market Uncertainty: Centralized procurement policies are expanding, leading to potential pricing headwinds and volume/value constraints in health system businesses.
• Cost Inflation: Input cost pressures have slightly increased, with a full-year impact expected in the high double-digit millions of euros at group level, partially offset by productivity measures.
• Regulatory Approval Risks: Return to the U.S. CPAP market via Sleep & Respiratory Care is contingent upon FDA approval of the consent decree, which is outside Philips' control.
• Supply Chain Disruptions: While resilience has improved, geopolitical uncertainty and demand for electronic components (including AI infrastructure) pose ongoing risks to supply reliability.

Q: Analyst asked about margin building blocks for 2027 given inflation/China headwinds and whether D&T orders will translate to medium-term sales growth targets.

A: CFO confirmed margins remain on track for the full-year guide (13.5%-14%) driven by Q4 volume leverage, innovation gross margin expansion, and productivity savings offsetting inflation. CEO highlighted that D&T Precision Diagnosis reached a turning point in Q3 with double-digit order growth, refilling the absolute order book so new orders now convert directly to sales. He noted ultrasound production ramp-up in Q4 will further support 2027 sales, underpinning confidence in achieving mid-single-digit sales CAGR ambitions.

Q: Analyst inquired if Connected Care order declines were purely timing or indicative of weaker demand, and requested visibility on China centralized procurement impacts.

A: CFO clarified that slips from Q2 occurred early in Q3, and while overall CC orders declined mid-single digits, this was against a >20% prior year comp. She emphasized that deal sizes are increasing, lengthening cycles, but no deals are being lost; Philips is actively dislodging incumbents in major North American accounts. Regarding China, CEO stated centralized procurement expands pricing pressure, keeping the market outlook cautious and stable for the full year, but growth is diversifying positively into North America, Europe, and Latin America to compensate.

Q: Analyst asked about capital allocation priorities (buybacks) post-deleveraging and business visibility amidst moving parts like inflation and order shifts.

A: CFO reiterated capital allocation priorities: 1) Organic growth, 2) Dividend, 3) M&A (increasingly active in intervention/monitoring), and 4) Share buybacks. She stressed that visibility has been good throughout the year, citing consistent delivery against unchanged guidance despite inflation. CEO added that supply chain resilience is bearing fruit with improved service KPIs, prioritizing fulfillment over inventory optimization, which customers value highly for trust and future orders.

Q: Analyst questioned why D&T orders had not previously translated into sales growth and how Connected Care monitoring deals are evolving.

A: CEO explained that previous order momentum was absorbed by declining absolute order book levels due to China sales and ultrasound phasing; now that the book is refilled, conversion to sales is accelerating. For Connected Care, Roy noted monitoring is complex and increasingly combines CapEx hardware with OpEx software (EMaaS), lengthening sales cycles but securing long-term recurring revenue. He highlighted strong customer engagement around patient safety and cybersecurity, with the U.S. Army as a key reference, driving continued share gains.